Allergan shares should be bought on weakness, says RBC Capital

theflyonthewall.com

After Allergan reported weaker than expected Q3 Botox sales, RBC Capital was encouraged that both the aesthetic and therapeutic businesses generated double-digit constant-currency growth. The firm maintains a $106 target and reiterates an Outperform rating.

View Comments (0)